Theravance Biopharma R&d Ip, LLC

Mandy Loo

Daniel D Long

Robert Murray McKinnell

Lan Jiang

Ryan Hudson

Lori Jean Van Orden

Donna A A Wilton

Gavin Ogawa

Patrick J Brassil

Kassandra Lepack

Adam D Hughes

Eric L Stangeland

Sheila M Zipfel

Daisuke Roland Saito

Erik Fenster

Jennifer Kozak

Svitlana Kulyk

Miroslav Rapta

Venkat R Thalladi

Weijiang Zhang

Steven D E Sullivan

Paul Allegretti

Marta Dabros

Jerry Nzerem

Xiaojun Huang

Tom M Lam

Breena Gloriana Fraga

Christopher Bailey

Christina Owens

Anthony Francesco Palermo

Diana Jin Wang

Matthew B Soellner

Donna Aa Wilton

Donna AA Wilton

The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.

Substituted pyrimidines and methods of use

The invention provides compounds which are prodrugs of a JAK inhibitor agent for the targeted delivery of the JAK inhibitor to the gastrointestinal tract of a mammal. The invention also provides pharmaceutical compositions comprising the compounds, methods of using the compounds to treat gastrointestinal inflammatory diseases, and processes and intermediates useful for preparing the compounds.

Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease

Substituted pyridines and methods of use

The invention relates to glucuronide prodrug compounds of Janus kinase (JAK) inhibitors having formula I: where W, Rand Aare as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.

Glucuronide prodrugs of Janus kinase inhibitors

The invention relates to glucuronide prodrug compounds of the Janus kinase (JAK) inhibitor tofacitinib having formula I: where Aand Rare as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.

Glucuronide prodrugs of tofacitinib

The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.

Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors

The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

Hepatitis C virus inhibitors

Inhibitors of hepatitic C virus

Inhibitors of hepatitis C virus

Growing community of inventors

San Jose, CA, United States of America

Mandy Loo